Influenza b treatment
Pro Research Analysisby 
Searched over 200M research papers
Influenza B Treatment: Current Options and Efficacy
Introduction to Influenza B Treatment
Influenza B virus is a significant cause of illness globally, particularly affecting children. Despite its impact, treatment options remain limited and often less effective compared to those for influenza A. This article synthesizes current research on the treatment of influenza B, focusing on antiviral drugs and emerging therapies.
Neuraminidase Inhibitors: Oseltamivir and Zanamivir
Effectiveness of Oseltamivir
Oseltamivir, a neuraminidase inhibitor, is commonly used to treat influenza B. However, studies indicate that it is less effective for influenza B compared to influenza A. A Japanese multicenter study found that the duration of fever and virus persistence were significantly longer in patients with influenza B treated with oseltamivir than those with influenza A, regardless of patient age or timing of administration4. Additionally, a systematic review and meta-analysis confirmed that oseltamivir reduces the median duration of symptoms but is less effective for influenza B than for influenza A5.
Zanamivir Efficacy
Zanamivir, another neuraminidase inhibitor, has shown similar efficacy to oseltamivir in reducing the duration of symptoms for influenza B. The same systematic review and meta-analysis reported that zanamivir reduced the median duration of symptoms in children, healthy adults, and high-risk populations5. However, the overall effectiveness of neuraminidase inhibitors for influenza B remains a subject of ongoing research and debate6 7.
Emerging Therapies
Anti-Influenza Hyperimmune Intravenous Immunoglobulin (hIVIG)
A recent double-blind, randomized, placebo-controlled trial evaluated the efficacy of anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) in adults hospitalized with influenza B. The study found that hIVIG treatment resulted in a significant rise in haemagglutination inhibition titres against influenza B. However, the overall clinical benefit was not superior to placebo, although subgroup analyses suggested potential benefits for influenza B patients1.
DAS181: A Host-Directed Antiviral
DAS181, a novel host-directed antiviral, has shown promise in reducing viral load in influenza B patients. A phase II clinical trial demonstrated that multiple doses of DAS181 significantly decreased viral load and viral shedding compared to placebo, indicating its potential as an effective treatment for influenza B8.
Baloxavir Marboxil
Baloxavir marboxil, a new antiviral with a unique mechanism of action, has been introduced as a promising treatment for influenza B. Recent studies suggest that baloxavir marboxil has a similar safety and efficacy profile to existing neuraminidase inhibitors, making it a viable option for managing influenza B infections9 10.
Conclusion
While traditional neuraminidase inhibitors like oseltamivir and zanamivir remain the primary treatments for influenza B, their efficacy is limited compared to influenza A. Emerging therapies such as hIVIG, DAS181, and baloxavir marboxil offer new hope for more effective management of influenza B. Continued research and clinical trials are essential to confirm the benefits of these new treatments and improve outcomes for patients with influenza B.
Sources and full results
Most relevant research papers on this topic
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial
HIVIG infusions are safe and effective for adults with influenza A or B infection, but more research is needed.
RCT
Large Human Trial
Rigorous Journal
Highly CitedNew options to treat influenza B
A new antibody targeting influenza B neuraminidase shows promise as a therapeutic option, showing promise in mice as a potential therapeutic option for influenza B.
Rigorous JournalRibavirin small-particle-aerosol treatment of influenza B virus infection
Aerosolized ribavirin showed no significant difference in febrile course or symptom score compared to placebo-treated patients for influenza B virus infection.
RCTA comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons.
Oseltamivir is less effective for influenza B than for influenza A in reducing fever duration and virus persistence, regardless of patient age or initial dose timing.
Observational StudyRigorous JournalHighly CitedEffectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials
Oseltamivir and zanamivir are clinically effective for treating and preventing influenza A and B, but evidence is limited for certain populations and prevention strategies.
Meta-AnalysisRigorous JournalHighly CitedNeuraminidase inhibitors for influenza B virus infection: efficacy and resistance.
Neuraminidase inhibitors show efficacy in treating influenza B virus infections, but resistance to these drugs is a challenge due to the increased risk of severe disease in pediatric patients.
Highly CitedBurden of influenza B virus infection and considerations for clinical management.
Influenza B virus infection causes significant morbidity and mortality, particularly in children, and recent data suggests that neuraminidase inhibitors and baloxavir are effective treatments for high-risk patients.
Literature ReviewA phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection.
DAS181 significantly reduced viral load in influenza-infected participants, warranting further clinical development of this novel host-directed therapy.
RCTRigorous JournalHighly CitedAntiviral Therapy for Influenza
Antiviral therapy shortens influenza course and relieves symptoms, but its effectiveness in reducing serious complications and hospitalization remains uncertain.
Literature ReviewAntiviral Drugs in Influenza
Baloxavir marboxil shows a similar safety and efficacy profile to existing antiviral drugs for treating influenza A and B, with further research on combination therapy promising results.
Rigorous Journal